{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:00:26Z","timestamp":1793066426112,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca and Allergan (formerly Actavis)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Infect Dis."],"published-print":{"date-parts":[[2016,6,1]]},"DOI":"10.1093\/cid\/ciw133","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T21:13:44Z","timestamp":1457558024000},"page":"1380-1389","source":"Crossref","is-referenced-by-count":350,"title":["Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program"],"prefix":"10.1093","volume":"62","author":[{"given":"John E.","family":"Mazuski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne B.","family":"Gasink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Broadhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg G.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Rank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Newell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Pachl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,3,8]]},"reference":[{"key":"2016051710432025000_62.11.1380.1","doi-asserted-by":"publisher","DOI":"10.1186\/1749-7922-8-3"},{"key":"2016051710432025000_62.11.1380.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2011.09.005"},{"key":"2016051710432025000_62.11.1380.3","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.80a.12182"},{"key":"2016051710432025000_62.11.1380.4","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"2016051710432025000_62.11.1380.5","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0674"},{"key":"2016051710432025000_62.11.1380.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.09.012"},{"key":"2016051710432025000_62.11.1380.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00851-12"},{"key":"2016051710432025000_62.11.1380.8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn320"},{"key":"2016051710432025000_62.11.1380.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00568-10"},{"key":"2016051710432025000_62.11.1380.10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks523"},{"key":"2016051710432025000_62.11.1380.11","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.748653"},{"key":"2016051710432025000_62.11.1380.12","unstructured":"Actavis Inc. Prescribing Information: AVYCAZ (ceftazidime-avibactam) for injection, for intravenous use. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206494lbl.pdf . Accessed 18 March 2015."},{"key":"2016051710432025000_62.11.1380.13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit128"},{"key":"2016051710432025000_62.11.1380.14","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I"},{"key":"2016051710432025000_62.11.1380.15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780040211"},{"key":"2016051710432025000_62.11.1380.16","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"2016051710432025000_62.11.1380.17","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.821109"},{"key":"2016051710432025000_62.11.1380.18","doi-asserted-by":"publisher","DOI":"10.1086\/590065"},{"key":"2016051710432025000_62.11.1380.19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.25.2.201"},{"key":"2016051710432025000_62.11.1380.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.2.229"},{"issue":"suppl 2","key":"2016051710432025000_62.11.1380.21","first-page":"S465","article-title":"Pharmacokinetics and tolerability of NXL104 in normal subjects and patients with varying degrees of renal insufficiency","volume":"16","author":"Merdjan","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2016051710432025000_62.11.1380.22","unstructured":"Cubist Pharmaceuticals. US prescribing information: Zerbaxa. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206829lbl.pdf . Accessed 17 March 2015."},{"key":"2016051710432025000_62.11.1380.23","unstructured":"Li J , Knebel W , Riggs M , Zhou D , Nichols W , Das S . Population pharmacokinetic modeling of ceftazidime (CAZ) and avibactam (AVI) in healthy volunteers and patients with complicated intra-abdominal Infection (cIAI) [abstract A-634]. In: 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco, CA, 2012."},{"key":"2016051710432025000_62.11.1380.24","unstructured":"Li J , Zhou D , Nichols W , Das S . Evaluation of ceftazidime-avibactam (CAZ-AVI) dose regimens for phase III study in patients with different renal function [abstract A-635]. In: 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy. San Francisco, CA, 2012."},{"key":"2016051710432025000_62.11.1380.25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ097"},{"key":"2016051710432025000_62.11.1380.26","doi-asserted-by":"publisher","DOI":"10.1186\/1749-7922-9-37"},{"key":"2016051710432025000_62.11.1380.27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00049-14"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/62\/11\/1380\/16789499\/ciw133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T19:56:47Z","timestamp":1503518207000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/ciw133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,8]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,5,17]]},"published-print":{"date-parts":[[2016,6,1]]}},"alternative-id":["10.1093\/cid\/ciw133"],"URL":"https:\/\/doi.org\/10.1093\/cid\/ciw133","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726209861.793549925","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,8]]}}}